Albiglutide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Albiglutide
Clinical data
Trade names Eperzan, Tanzeum
Licence data EMA:Link, US FDA:link
Pregnancy cat. C (US)
Legal status -only (US)
Routes Subcutaneous (SC)
Pharmacokinetic data
Half-life 4-7 days
Identifiers
CAS number 782500-75-8
ATC code None
Chemical data
Formula C3232H5032N864O979S41 
Mol. mass 72,970 g/mol

Albiglutide (tradenames Eperzan and Tanzeum) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. The drug was invented by Human Genome Sciences and was developed in collaboration with GSK.[1]

Albiglutide has a half-life of four to seven days, which is considerably longer than the other two GLP-1 analogs approved for market use, exenatide (Byetta) and liraglutide (Victoza).[2] [3] GLP-1 drugs are currently only available for subcutaneous administration on a daily basis, so a GLP-1 drug with a longer half-life is desirable. Such a drug would only need to be injected biweekly or weekly instead of daily, reducing the discomfort and inconvenience of GLP-1 administration considerably.

It has not yet been determined whether albiglutide is as effective an antidiabetic agent as GLP-1 drugs currently on the market, and final data remains to be published regarding the incidence of adverse effects related to the drug. To evaluate the efficacy and safety of the drug, albiglutide is undergoing eight Phase III clinical trials. Four of these trials should report useful data by end 2010.[4][dated info]6 GSK filed for FDA approval on 01/14/2013 and European Medical Agency (EMA) on 03/07/2013. On 08/02/2013 GSK released a press release pushing the marketing date 3 months to 04/15/2014.

In March 2014, GlaxoSmithKline PLC received approval from the European Commission to market albiglutide under the name 'Eperzan'. [5]

In April 2014, the FDA approved albiglutide under the name Tanzeum.[6]

See also[edit]

exenatide (Byetta)
liraglutide (Victoza)
taspoglutide

References[edit]


{( http://www.gsk.com/media/press-releases/2013/regulatory-update--albiglutide-us-pdufa-date-extended-by-three-m.html )}